The Brinzei MDMA-PTSD Protocol: Addressing the Food and Drug Administration’s Breaking Blind Concerns with Precision Approaches to Post-Traumatic Stress Disorder Treatment
Preprints.org October 3, 2025 Octavian Brinzei preprint
MDMA-assisted therapy reduces PTSD symptoms in multiple clinical trials, but regulatory rejection based on flawed blinding methods highlights a contradiction: the drug's strong psychoactive effects make true placebo-controlled trials impossible. This paper introduces the Trauma-Affective Memory Loop (TAML), a model of how traumatic memories are stored and reinforced. MDMA reduces fear signals, creating a temporary "therapeutic window" for safe trauma reprocessing. Acute, one-time traumas may resolve in one to three sessions, while complex or developmental trauma may need repeated treatment. A new quadruple-masked trial design, the Brinzei MDMA-PTSD Protocol (BMPP), limits bias while allowing effective therapy delivery.